Development and therapeutic implications of selective histone deacetylase 6 inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 16, 2013, Pages 6297-6313

  Kalin, Jay H ^a,b   Bergman, Joel A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 6 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW;

DISEASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS;

EID: 84883155892     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4001659     Document Type: Review

References (154)

1. Kelly, T. K.; De Carvalho, D. D.; Jones, P. A. Epigenetic modifications as therapeutic targets Nat. Biotechnol. 2010, 28, 1069-1078
2. Blair, L. P.; Yan, Q. Epigenetic mechanisms in commonly occurring cancers DNA Cell Biol. 2012, 31 (Suppl. 1) S49-S61
3. Greer, J. M.; McCombe, P. A. The role of epigenetic mechanisms and processes in autoimmune disorders Biologics 2012, 6, 307-327
4. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 2007, 12, 1247-1252
5. StatBite: FDA oncology drug product approvals in 2009. J. Natl. Cancer Inst. 2010, 102, 219.
6. Bieliauskas, A. V.; Pflum, M. K. Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 2008, 37, 1402-1413
7. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 2003, 370, 737-749
8. Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 2010, 6, 238-243
9. Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform selectivity in histone deacetylase inhibitors Curr. Pharm. Des. 2008, 14, 505-528
10. Kozikowski, A. P.; Chen, Y.; Gaysin, A.; Chen, B.; D'Annibale, M. A.; Suto, C. M.; Langley, B. C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies J. Med. Chem. 2007, 50, 3054-3061
11. Kim, D.; Frank, C. L.; Dobbin, M. M.; Tsunemoto, R. K.; Tu, W.; Peng, P. L.; Guan, J. S.; Lee, B. H.; Moy, L. Y.; Giusti, P.; Broodie, N.; Mazitschek, R.; Delalle, I.; Haggarty, S. J.; Neve, R. L.; Lu, Y.; Tsai, L. H. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity Neuron 2008, 60, 803-817
12. Chen, Y.; He, R.; D'Annibale, M. A.; Langley, B.; Kozikowski, A. P. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors ChemMedChem 2009, 4, 842-852
13. Best, J. D.; Carey, N. Epigenetic therapies for non-oncology indications Drug Discovery Today 2010, 15, 1008-1014
14. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21
15. Langley, B.; D'Annibale, M. A.; Suh, K.; Ayoub, I.; Tolhurst, A.; Bastan, B.; Yang, L.; Ko, B.; Fisher, M.; Cho, S.; Beal, M. F.; Ratan, R. R. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection J. Neurosci. 2008, 28, 163-176
16. Welberg, L. Neurodegenerative disorders: HDAC2 is the one Nat. Rev. Drug Discovery 2009, 8, 538-539
17. Zhang, Y.; Kwon, S.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H. L.; Chua, K.; Lombard, D.; Mizeracki, A.; Matthias, G.; Alt, F. W.; Khochbin, S.; Matthias, P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally Mol. Cell. Biol. 2008, 28, 1688-1701
18. Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4868-4873
19. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394
20. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458
21. Luxton, G. W.; Gundersen, G. G. HDAC6-pack: cortactin acetylation joins the brew Dev. Cell 2007, 13, 161-162
22. Hook, S. S.; Orian, A.; Cowley, S. M.; Eisenman, R. N. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13425-13430
23. Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol. Cell 2005, 18, 601-607
24. Palijan, A.; Fernandes, I.; Bastien, Y.; Tang, L.; Verway, M.; Kourelis, M.; Tavera-Mendoza, L. E.; Li, Z.; Bourdeau, V.; Mader, S.; Yang, X. J.; White, J. H. Function of histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR J. Biol. Chem. 2009, 284, 30264-30274
25. Wang, L.; Xiang, S.; Williams, K. A.; Dong, H.; Bai, W.; Nicosia, S. V.; Khochbin, S.; Bepler, G.; Zhang, X. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells PLoS One 2012, 7, e44265
26. Sung, Y. M.; Lee, T.; Yoon, H.; Dibattista, A. M.; Song, J. M.; Sohn, Y.; Moffat, E. I.; Turner, R. S.; Jung, M.; Kim, J.; Hoe, H. S. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease Exp. Neurol. 2012, 239C, 192-201
27. Zhang, Y.; Gilquin, B.; Khochbin, S.; Matthias, P. Two catalytic domains are required for protein deacetylation J. Biol. Chem. 2006, 281, 2401-2404
28. Zou, H.; Wu, Y.; Navre, M.; Sang, B. C. Characterization of the two catalytic domains in histone deacetylase 6 Biochem. Biophys. Res. Commun. 2006, 341, 45-50
29. Bertos, N. R.; Wang, A. H.; Yang, X. J. Class II histone deacetylases: structure, function, and regulation Biochem. Cell Biol. 2001, 79, 243-252
30. Valenzuela-Fernandez, A.; Cabrero, J. R.; Serrador, J. M.; Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions Trends Cell Biol. 2008, 18, 291-297
31. Kawaguchi, Y.; Kovacs, J. J.; McLaurin, A.; Vance, J. M.; Ito, A.; Yao, T. P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 2003, 115, 727-738
32. Zhang, X.; Yuan, Z.; Zhang, Y.; Yong, S.; Salas-Burgos, A.; Koomen, J.; Olashaw, N.; Parsons, J. T.; Yang, X. J.; Dent, S. R.; Yao, T. P.; Lane, W. S.; Seto, E. HDAC6 modulates cell motility by altering the acetylation level of cortactin Mol. Cell 2007, 27, 197-213
33. Bulinski, J. C. Microtubule modification: acetylation speeds anterograde traffic flow Curr. Biol. 2007, 17, R18-R20
34. Reed, N. A.; Cai, D.; Blasius, T. L.; Jih, G. T.; Meyhofer, E.; Gaertig, J.; Verhey, K. J. Microtubule acetylation promotes kinesin-1 binding and transport Curr. Biol. 2006, 16, 2166-2172
35. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelieres, F. P.; King, S. J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation J. Neurosci. 2007, 27, 3571-3583
36. Destaing, O.; Saltel, F.; Gilquin, B.; Chabadel, A.; Khochbin, S.; Ory, S.; Jurdic, P. A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts J. Cell Sci. 2005, 118, 2901-2911
37. Boyault, C.; Zhang, Y.; Fritah, S.; Caron, C.; Gilquin, B.; Kwon, S. H.; Garrido, C.; Yao, T. P.; Vourc'h, C.; Matthias, P.; Khochbin, S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates Genes Dev. 2007, 21, 2172-2181
38. Parmigiani, R. B.; Xu, W. S.; Venta-Perez, G.; Erdjument-Bromage, H.; Yaneva, M.; Tempst, P.; Marks, P. A. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9633-9638
39. d'Ydewalle, C.; Krishnan, J.; Chiheb, D. M.; Van Damme, P.; Irobi, J.; Kozikowski, A. P.; Vanden Berghe, P.; Timmerman, V.; Robberecht, W.; Van Den Bosch, L. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease Nat. Med. 2011, 17, 968-974
40. d'Ydewalle, C.; Bogaert, E.; Van Den Bosch, L. HDAC6 at the intersection of neuroprotection and neurodegeneration Traffic 2012, 13, 771-779
41. Li, G.; Jiang, H.; Chang, M.; Xie, H.; Hu, L. HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases J. Neurol. Sci. 2011, 304, 1-8
42. Aldana-Masangkay, G. I.; Sakamoto, K. M. The role of HDAC6 in cancer J. Biomed. Biotechnol. 2011, 2011, 875824
43. Lee, Y. S.; Lim, K. H.; Guo, X.; Kawaguchi, Y.; Gao, Y.; Barrientos, T.; Ordentlich, P.; Wang, X. F.; Counter, C. M.; Yao, T. P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis Cancer Res. 2008, 68, 7561-7569
44. Kaluza, D.; Kroll, J.; Gesierich, S.; Yao, T. P.; Boon, R. A.; Hergenreider, E.; Tjwa, M.; Rossig, L.; Seto, E.; Augustin, H. G.; Zeiher, A. M.; Dimmeler, S.; Urbich, C. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin EMBO J. 2011, 30, 4142-4156
45. Santo, L.; Hideshima, T.; Kung, A. L.; Tseng, J. C.; Tamang, D.; Yang, M.; Jarpe, M.; van Duzer, J. H.; Mazitschek, R.; Ogier, W. C.; Cirstea, D.; Rodig, S.; Eda, H.; Scullen, T.; Canavese, M.; Bradner, J.; Anderson, K. C.; Jones, S. S.; Raje, N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 2012, 119, 2579-2589
46. Rey, M.; Irondelle, M.; Waharte, F.; Lizarraga, F.; Chavrier, P. HDAC6 is required for invadopodia activity and invasion by breast tumor cells Eur. J. Cell Biol. 2011, 90, 128-135
47. Penela, P.; Lafarga, V.; Tapia, O.; Rivas, V.; Nogues, L.; Lucas, E.; Vila-Bedmar, R.; Murga, C.; Mayor, F., Jr. Roles of GRK2 in cell signaling beyond GPCR desensitization: GRK2-HDAC6 interaction modulates cell spreading and motility Sci. Signal. 2012, 5, pt3
48. Zuo, Q.; Wu, W.; Li, X.; Zhao, L.; Chen, W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin Oncol. Rep. 2012, 27, 819-824
49. Kanno, K.; Kanno, S.; Nitta, H.; Uesugi, N.; Sugai, T.; Masuda, T.; Wakabayashi, G.; Maesawa, C. Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells Oncol. Rep. 2012, 28, 867-873
50. Wickstrom, S. A.; Masoumi, K. C.; Khochbin, S.; Fassler, R.; Massoumi, R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin EMBO J. 2010, 29, 131-144
51. Hideshima, T.; Bradner, J. E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S. L.; Anderson, K. C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8567-8572
52. Hideshima, T.; Anderson, K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma Nat. Rev. Cancer 2002, 2, 927-937
53. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 2010, 132, 10842-10846
54. Castro-Castro, A.; Janke, C.; Montagnac, G.; Paul-Gilloteaux, P.; Chavrier, P. ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion Eur. J. Cell Biol. 2012, 91, 950-960
55. Hsieh, T. H.; Tsai, C. F.; Hsu, C. Y.; Kuo, P. L.; Lee, J. N.; Chai, C. Y.; Hou, M. F.; Chang, C. C.; Long, C. Y.; Ko, Y. C.; Tsai, E. M. Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells Toxicol. Sci. 2012, 128, 365-376
56. Lafarga, V.; Aymerich, I.; Tapia, O.; Mayor, F., Jr.; Penela, P. A novel GRK2/HDAC6 interaction modulates cell spreading and motility EMBO J. 2012, 31, 856-869
57. Tran, A. D.; Marmo, T. P.; Salam, A. A.; Che, S.; Finkelstein, E.; Kabarriti, R.; Xenias, H. S.; Mazitschek, R.; Hubbert, C.; Kawaguchi, Y.; Sheetz, M. P.; Yao, T. P.; Bulinski, J. C. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions J. Cell Sci. 2007, 120, 1469-1479
58. Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M. K.; Wang, M. C.; Chan, K. C.; Bristow, R. E.; Mazitschek, R.; Bradner, J.; Roden, R. B. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor Clin. Cancer Res. 2008, 14, 7340-7347
59. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin Org. Lett. 2001, 3, 4239-4242
60. Gibbs, A.; Schwartzman, J.; Deng, V.; Alumkal, J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6 Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16663-16668
61. Myzak, M. C.; Tong, P.; Dashwood, W. M.; Dashwood, R. H.; Ho, E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects Exp. Biol. Med. (Maywood, NJ, U. S.) 2007, 232, 227-234
62. Singh, S. V.; Warin, R.; Xiao, D.; Powolny, A. A.; Stan, S. D.; Arlotti, J. A.; Zeng, Y.; Hahm, E. R.; Marynowski, S. W.; Bommareddy, A.; Desai, D.; Amin, S.; Parise, R. A.; Beumer, J. H.; Chambers, W. H. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells Cancer Res. 2009, 69, 2117-2125
63. Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 20003-20008
64. Kamemura, K.; Ito, A.; Shimazu, T.; Matsuyama, A.; Maeda, S.; Yao, T. P.; Horinouchi, S.; Khochbin, S.; Yoshida, M. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells Biochem. Biophys. Res. Commun. 2008, 374, 84-89
65. Jung, K. H.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Bae, H. J.; Chang, Y. G.; Kim, M. G.; Park, W. S.; Lee, J. Y.; Lee, S. Y.; Chu, I. S.; Nam, S. W. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer Hepatology 2012, 56, 644-657
66. Bergman, J. A.; Woan, K.; Perez-Villarroel, P.; Villagra, A.; Sotomayor, E. M.; Kozikowski, A. P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth J. Med. Chem. 2012, 55, 9891-9899
67. Kerr, E.; Holohan, C.; McLaughlin, K. M.; Majkut, J.; Dolan, S.; Redmond, K.; Riley, J.; McLaughlin, K.; Stasik, I.; Crudden, M.; Van Schaeybroeck, S.; Fenning, C.; O'Connor, R.; Kiely, P.; Sgobba, M.; Haigh, D.; Johnston, P. G.; Longley, D. B. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis Cell Death Differ. 2012, 19, 1317-1327
68. Aldana-Masangkay, G. I.; Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A. K.; Hsieh, Y. T.; Kim, Y. M.; Lomenick, B.; Okemoto, K.; Landaw, E. M.; Wang, D.; Mazitschek, R.; Bradner, J. E.; Sakamoto, K. M. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells Leuk. Lymphoma 2011, 52, 1544-1555
69. Hackanson, B.; Rimmele, L.; Benkisser, M.; Abdelkarim, M.; Fliegauf, M.; Jung, M.; Lubbert, M. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia Leuk. Res. 2012, 36, 1055-1062
70. Scott, G. K.; Marx, C.; Berger, C. E.; Saunders, L. R.; Verdin, E.; Schafer, S.; Jung, M.; Benz, C. C. Destabilization of ERBB2 transcripts by targeting 3′ untranslated region messenger RNA associated HuR and histone deacetylase-6 Mol. Cancer Res. 2008, 6, 1250-1258
71. Kawada, J.; Zou, P.; Mazitschek, R.; Bradner, J. E.; Cohen, J. I. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis J. Biol. Chem. 2009, 284, 17102-17109
72. Hancock, W. W.; Akimova, T.; Beier, U. H.; Liu, Y.; Wang, L. HDAC inhibitor therapy in autoimmunity and transplantation Ann. Rheum. Dis. 2012, 71 (Suppl. 2) i46-i54
73. Beier, U. H.; Akimova, T.; Liu, Y.; Wang, L.; Hancock, W. W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells Curr. Opin. Immunol. 2011, 23, 670-678
74. Pan, F.; Fan, H.; Liu, Z.; Jiang, S. T cell signaling targets for enhancing regulatory or effector function Sci. Signaling 2012, 5, pe32
75. Rivieccio, M. A.; Brochier, C.; Willis, D. E.; Walker, B. A.; D'Annibale, M. A.; McLaughlin, K.; Siddiq, A.; Kozikowski, A. P.; Jaffrey, S. R.; Twiss, J. L.; Ratan, R. R.; Langley, B. HDAC6 is a target for protection and regeneration following injury in the nervous system Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 19599-19604
76. de Zoeten, E. F.; Wang, L.; Butler, K.; Beier, U. H.; Akimova, T.; Sai, H.; Bradner, J. E.; Mazitschek, R.; Kozikowski, A. P.; Matthias, P.; Hancock, W. W. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells Mol. Cell. Biol. 2011, 31, 2066-2078
77. Akimova, T.; Beier, U. H.; Liu, Y.; Wang, L.; Hancock, W. W. Histone/protein deacetylases and T-cell immune responses Blood 2012, 119, 2443-2451
78. Saha, R. N.; Pahan, K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis Cell Death Differ. 2006, 13, 539-550
79. Chuang, D. M.; Leng, Y.; Marinova, Z.; Kim, H. J.; Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci. 2009, 32, 591-601
80. Abel, T.; Zukin, R. S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr. Opin. Pharmacol. 2008, 8, 57-64
81. Chen, Y. T.; Zang, X. F.; Pan, J.; Zhu, X. L.; Chen, F.; Chen, Z. B.; Xu, Y. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection Clin. Exp. Pharmacol. Physiol. 2012, 39, 751-758
82. Zhang, B.; West, E. J.; Van, K. C.; Gurkoff, G. G.; Zhou, J.; Zhang, X. M.; Kozikowski, A. P.; Lyeth, B. G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats Brain Res. 2008, 1226, 181-191
83. Cook, C.; Gendron, T. F.; Scheffel, K.; Carlomagno, Y.; Dunmore, J.; DeTure, M.; Petrucelli, L. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation Hum. Mol. Genet. 2012, 21, 2936-2945
84. Lee, J. Y.; Nagano, Y.; Taylor, J. P.; Lim, K. L.; Yao, T. P. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy J. Cell Biol. 2010, 189, 671-679
85. Nixon, R. A.; Wegiel, J.; Kumar, A.; Yu, W. H.; Peterhoff, C.; Cataldo, A.; Cuervo, A. M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study J. Neuropathol. Exp. Neurol. 2005, 64, 113-122
86. Van Den Heuvel, C.; Thornton, E.; Vink, R. Traumatic brain injury and Alzheimer's disease: a review Prog. Brain Res. 2007, 161, 303-316
87. Zhang, X. H.; Lei, H.; Liu, A. J.; Zou, Y. X.; Shen, F. M.; Su, D. F. Increased oxidative stress is responsible for severer cerebral infarction in stroke-prone spontaneously hypertensive rats CNS Neurosci. Ther. 2011, 17, 590-598
88. Xia, W.; Han, J.; Huang, G.; Ying, W. Inflammation in ischaemic brain injury: current advances and future perspectives Clin. Exp. Pharmacol. Physiol. 2010, 37, 253-258
89. Bardai, F. H.; D'Mello, S. R. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta J. Neurosci. 2011, 31, 1746-1751
90. Kim, H. J.; Leeds, P.; Chuang, D. M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain J. Neurochem. 2009, 110, 1226-1240
91. Bush, E. W.; McKinsey, T. A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors Circ. Res. 2010, 106, 272-284
92. Berry, J. M.; Cao, D. J.; Rothermel, B. A.; Hill, J. A. Histone deacetylase inhibition in the treatment of heart disease Expert Opin. Drug Saf. 2008, 7, 53-67
93. Granger, A.; Abdullah, I.; Huebner, F.; Stout, A.; Wang, T.; Huebner, T.; Epstein, J. A.; Gruber, P. J. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice FASEB J. 2008, 22, 3549-3560
94. Zhao, T. C.; Zhang, L. X.; Cheng, G.; Liu, J. T. gp-91 mediates histone deacetylase inhibition-induced cardioprotection Biochim. Biophys. Acta 2010, 1803, 872-880
95. Zhang, L. X.; Zhao, Y.; Cheng, G.; Guo, T. L.; Chin, Y. E.; Liu, P. Y.; Zhao, T. C. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition Am. J. Physiol.: Heart Circ. Physiol. 2010, 298, H2154-H2163
96. Zhao, T. C.; Cheng, G.; Zhang, L. X.; Tseng, Y. T.; Padbury, J. F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury Cardiovasc. Res. 2007, 76, 473-481
97. Iyer, A.; Fenning, A.; Lim, J.; Le, G. T.; Reid, R. C.; Halili, M. A.; Fairlie, D. P.; Brown, L. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats Br. J. Pharmacol. 2010, 159, 1408-1417
98. Lemon, D. D.; Horn, T. R.; Cavasin, M. A.; Jeong, M. Y.; Haubold, K. W.; Long, C. S.; Irwin, D. C.; McCune, S. A.; Chung, E.; Leinwand, L. A.; McKinsey, T. A. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension J. Mol. Cell. Cardiol. 2011, 51, 41-50
99. Chen, S.; Owens, G. C.; Makarenkova, H.; Edelman, D. B. HDAC6 regulates mitochondrial transport in hippocampal neurons PLoS One 2010, 5, e10848
100. Gao, Y. S.; Hubbert, C. C.; Yao, T. P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation J. Biol. Chem. 2010, 285, 11219-11226
101. Hollenbeck, P. J.; Saxton, W. M. The axonal transport of mitochondria J. Cell Sci. 2005, 118, 5411-5419
102. Hammond, J. W.; Huang, C. F.; Kaech, S.; Jacobson, C.; Banker, G.; Verhey, K. J. Posttranslational modifications of tubulin and the polarized transport of kinesin-1 in neurons Mol. Biol. Cell 2010, 21, 572-583
103. Kamemura, K.; Ogawa, M.; Ohkubo, S.; Ohtsuka, Y.; Shitara, Y.; Komiya, T.; Maeda, S.; Ito, A.; Yoshida, M. Depression of mitochondrial metabolism by downregulation of cytoplasmic deacetylase, HDAC6 FEBS Lett. 2012, 586, 1379-1383
104. d'Ydewalle, C.; Benoy, V.; Van Den Bosch, L. Charcot-Marie-Tooth disease: emerging mechanisms and therapies Int. J. Biochem. Cell Biol. 2012, 44, 1299-1304
105. Lee, J. Y.; Koga, H.; Kawaguchi, Y.; Tang, W.; Wong, E.; Gao, Y. S.; Pandey, U. B.; Kaushik, S.; Tresse, E.; Lu, J.; Taylor, J. P.; Cuervo, A. M.; Yao, T. P. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy EMBO J. 2010, 29, 969-980
106. True, O.; Matthias, P. Interplay between histone deacetylases and autophagy-from cancer therapy to neurodegeneration Immunol. Cell Biol. 2012, 90, 78-84
107. Yao, T. P. The role of ubiquitin in autophagy-dependent protein aggregate processing Genes Cancer 2010, 1, 779-786
108. Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; Yokoyama, M.; Mishima, K.; Saito, I.; Okano, H.; Mizushima, N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 2006, 441, 885-889
109. Komatsu, M.; Waguri, S.; Chiba, T.; Murata, S.; Iwata, J.; Tanida, I.; Ueno, T.; Koike, M.; Uchiyama, Y.; Kominami, E.; Tanaka, K. Loss of autophagy in the central nervous system causes neurodegeneration in mice Nature 2006, 441, 880-884
110. Cecarini, V.; Bonfili, L.; Cuccioloni, M.; Mozzicafreddo, M.; Rossi, G.; Buizza, L.; Uberti, D.; Angeletti, M.; Eleuteri, A. M. Crosstalk between the ubiquitin-proteasome system and autophagy in a human cellular model of Alzheimer's disease Biochim. Biophys. Acta 2012, 1822, 1741-1751
111. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Rev. 2000, 33, 95-130
112. Dickson, D. W. Tau and synuclein and their role in neuropathology Brain Pathol. 1999, 9, 657-661
113. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W. H.; Browne, S. E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T. M.; Wolozin, B.; Hardy, J.; Hutton, M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation Hum. Mol. Genet. 2004, 13, 703-714
114. Shimura, H.; Schwartz, D.; Gygi, S. P.; Kosik, K. S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival J. Biol. Chem. 2004, 279, 4869-4876
115. Dickey, C. A.; Yue, M.; Lin, W. L.; Dickson, D. W.; Dunmore, J. H.; Lee, W. C.; Zehr, C.; West, G.; Cao, S.; Clark, A. M.; Caldwell, G. A.; Caldwell, K. A.; Eckman, C.; Patterson, C.; Hutton, M.; Petrucelli, L. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species J. Neurosci. 2006, 26, 6985-6996
116. Dickey, C. A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R. M.; Dunmore, J.; Ash, P.; Shoraka, S.; Zlatkovic, J.; Eckman, C. B.; Patterson, C.; Dickson, D. W.; Nahman, N. S., Jr.; Hutton, M.; Burrows, F.; Petrucelli, L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Invest. 2007, 117, 648-658
117. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J. Biol. Chem. 2005, 280, 26729-26734
118. Murphy, P. J.; Morishima, Y.; Kovacs, J. J.; Yao, T. P.; Pratt, W. B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone J. Biol. Chem. 2005, 280, 33792-33799
119. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J. E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 2008, 112, 1886-1893
120. Yang, Y.; Rao, R.; Shen, J.; Tang, Y.; Fiskus, W.; Nechtman, J.; Atadja, P.; Bhalla, K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion Cancer Res. 2008, 68, 4833-4842
121. De Strooper, B.; Vassar, R.; Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease Nat. Rev. Neurol. 2010, 6, 99-107
122. Konsoula, R.; Jung, M. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors Int. J. Pharm. 2008, 361, 19-25
123. Konsoula, Z.; Cao, H.; Velena, A.; Jung, M. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity Int. J. Radiat. Oncol., Biol., Phys. 2011, 79, 1541-1548
124. Jung, M.; Velena, A.; Chen, B.; Petukhov, P. A.; Kozikowski, A. P.; Dritschilo, A. Novel HDAC inhibitors with radiosensitizing properties Radiat. Res. 2005, 163, 488-493
125. Kim, C.; Choi, H.; Jung, E. S.; Lee, W.; Oh, S.; Jeon, N. L.; Mook-Jung, I. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons PLoS One 2012, 7, e42983
126. Zilberman, Y.; Ballestrem, C.; Carramusa, L.; Mazitschek, R.; Khochbin, S.; Bershadsky, A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6 J. Cell Sci. 2009, 122, 3531-3541
127. Fukushima, N.; Furuta, D.; Hidaka, Y.; Moriyama, R.; Tsujiuchi, T. Post-translational modifications of tubulin in the nervous system J. Neurochem. 2009, 109, 683-693
128. Hammond, J. W.; Cai, D.; Verhey, K. J. Tubulin modifications and their cellular functions Curr. Opin. Cell Biol. 2008, 20, 71-76
129. Dent, E. W.; Gertler, F. B. Cytoskeletal dynamics and transport in growth cone motility and axon guidance Neuron 2003, 40, 209-227
130. Calkins, M. J.; Reddy, P. H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons Biochim. Biophys. Acta 2011, 1812, 507-513
131. Decker, H.; Lo, K. Y.; Unger, S. M.; Ferreira, S. T.; Silverman, M. A. Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons J. Neurosci. 2010, 30, 9166-9171
132. Du, H.; Guo, L.; Yan, S.; Sosunov, A. A.; McKhann, G. M.; Yan, S. S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 18670-18675
133. Yang, X. J.; Gregoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication Mol. Cell. Biol. 2005, 25, 2873-2884
134. Kozikowski, A. P.; Chen, Y.; Gaysin, A. M.; Savoy, D. N.; Billadeau, D. D.; Kim, K. H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth ChemMedChem 2008, 3, 487-501
135. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6 J. Med. Chem. 2008, 51, 4370-4373
136. Tapadar, S.; He, R.; Luchini, D. N.; Billadeau, D. D.; Kozikowski, A. P. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity Bioorg. Med. Chem. Lett. 2009, 19, 3023-3026
137. Kalin, J. H.; Zhang, H.; Gaudrel-Grosay, S.; Vistoli, G.; Kozikowski, A. P. Chiral mercaptoacetamides display enantioselective inhibition of histone deacetylase 6 and exhibit neuroprotection in cortical neuron models of oxidative stress ChemMedChem 2012, 7, 425-439
138. Chen, Y.; Lopez-Sanchez, M.; Savoy, D. N.; Billadeau, D. D.; Dow, G. S.; Kozikowski, A. P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum J. Med. Chem. 2008, 51, 3437-3448
139. Kalin, J. H.; Butler, K. V.; Akimova, T.; Hancock, W. W.; Kozikowski, A. P. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells J. Med. Chem. 2012, 55, 639-651
140. Bieliauskas, A. V.; Weerasinghe, S. V.; Pflum, M. K. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid Bioorg. Med. Chem. Lett. 2007, 17, 2216-2219
141. Choi, S. E.; Weerasinghe, S. V.; Pflum, M. K. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity Bioorg. Med. Chem. Lett. 2011, 21, 6139-6142
142. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerhauser, C.; Jung, M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells J. Med. Chem. 2002, 45, 3296-3309
143. Schafer, S.; Saunders, L.; Eliseeva, E.; Velena, A.; Jung, M.; Schwienhorst, A.; Strasser, A.; Dickmanns, A.; Ficner, R.; Schlimme, S.; Sippl, W.; Verdin, E. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs) Bioorg. Med. Chem. 2008, 16, 2011-2033
144. Schafer, S.; Saunders, L.; Schlimme, S.; Valkov, V.; Wagner, J. M.; Kratz, F.; Sippl, W.; Verdin, E.; Jung, M. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors ChemMedChem 2009, 4, 283-290
145. Suzuki, T.; Nagano, Y.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates Bioorg. Med. Chem. Lett. 2003, 13, 4321-4326
146. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317
147. Suzuki, T.; Matsuura, A.; Kouketsu, A.; Nakagawa, H.; Miyata, N. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design Bioorg. Med. Chem. Lett. 2005, 15, 331-335
148. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype selective substrates for histone deacetylases J. Med. Chem. 2004, 47, 5235-5243
149. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate J. Med. Chem. 2006, 49, 4809-4812
150. Smil, D. V.; Manku, S.; Chantigny, Y. A.; Leit, S.; Wahhab, A.; Yan, T.
151. Inks, E. S.; Josey, B. J.; Jesinkey, S. R.; Chou, C. J. A novel class of small molecule inhibitors of HDAC6 ACS Chem. Biol. 2012, 7, 331-339
152. Bantscheff, M.; Hopf, C.; Savitski, M. M.; Dittmann, A.; Grandi, P.; Michon, A. M.; Schlegl, J.; Abraham, Y.; Becher, I.; Bergamini, G.; Boesche, M.; Delling, M.; Dumpelfeld, B.; Eberhard, D.; Huthmacher, C.; Mathieson, T.; Poeckel, D.; Reader, V.; Strunk, K.; Sweetman, G.; Kruse, U.; Neubauer, G.; Ramsden, N. G.; Drewes, G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 2011, 29, 255-265
153. Jones, P.; Bottomley, M. J.; Carfi, A.; Cecchetti, O.; Ferrigno, F.; Lo Surdo, P.; Ontoria, J. M.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Steinkuhler, C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3456-3461
154. Ontoria, J. M.; Altamura, S.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Muraglia, E.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuhler, C.; Jones, P. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy J. Med. Chem. 2009, 52, 6782-6789